Athira Pharma, Inc.
ATHANASDAQHealthcare
$6.75
$-0.44(-6.12%)
Market Cap$26621237
P/E Ratio—
52W High$8.36
52W Low$2.1955
Athira Pharma, Inc. (ATHA) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ATHA · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
-$1.73
Est. -$1.90 · +8.9%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▲ Beat EPS✓ 1-Quarter EPS Beat Streak
ATHA reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 7, 2026 | -$1.90 | -$1.73 | +8.9% | — | — | — |
| ▼ Q1 FY2026 | Feb 25, 2026 | -$0.58 | -$3.90 | -577.8% | — | — | — |
| ▼ Q4 FY2025 | Nov 6, 2025 | -$1.06 | -$1.68 | -58.5% | — | — | — |
| — Q3 FY2025 | Aug 7, 2025 | -$1.80 | -$1.80 | +0.0% | — | — | — |
| ▼ Q2 FY2025 | May 9, 2025 | -$0.20 | -$0.23 | -15.0% | — | — | — |
| ▼ Q1 FY2025 | Feb 27, 2025 | -$0.23 | -$0.39 | -69.6% | — | — | — |
| ▲ Q4 FY2024 | Nov 7, 2024 | -$0.80 | -$0.75 | +6.3% | — | — | — |
| ▲ Q3 FY2024 | Aug 1, 2024 | -$0.75 | -$0.70 | +6.7% | — | — | — |
Q2 FY2026
May 7, 2026Beat
EPS Actual
-$1.73
EPS Est.
-$1.90
EPS Surpr.
+8.9%
Revenue
—
Q1 FY2026
Feb 25, 2026Miss
EPS Actual
-$3.90
EPS Est.
-$0.58
EPS Surpr.
-577.8%
Revenue
—
Q4 FY2025
Nov 6, 2025Miss
EPS Actual
-$1.68
EPS Est.
-$1.06
EPS Surpr.
-58.5%
Revenue
—
Q3 FY2025
Aug 7, 2025
EPS Actual
-$1.80
EPS Est.
-$1.80
EPS Surpr.
+0.0%
Revenue
—
Q2 FY2025
May 9, 2025Miss
EPS Actual
-$0.23
EPS Est.
-$0.20
EPS Surpr.
-15.0%
Revenue
—
Q1 FY2025
Feb 27, 2025Miss
EPS Actual
-$0.39
EPS Est.
-$0.23
EPS Surpr.
-69.6%
Revenue
—
Q4 FY2024
Nov 7, 2024Beat
EPS Actual
-$0.75
EPS Est.
-$0.80
EPS Surpr.
+6.3%
Revenue
—
Q3 FY2024
Aug 1, 2024Beat
EPS Actual
-$0.70
EPS Est.
-$0.75
EPS Surpr.
+6.7%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $-0.50 | $-0.50 | $-0.50 | 1 |
| Q3 FY2026 | $-0.50 | $-0.50 | $-0.50 | 1 |
| Q2 FY2026 | $-0.60 | $-0.60 | $-0.60 | 1 |
| Q1 FY2026 | $-1.90 | $-1.90 | $-1.90 | 1 |
| Q4 FY2025 | $-0.58 | $-0.58 | $-0.58 | 1 |
| Q3 FY2025 | $-1.06 | $-1.06 | $-1.06 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 7, 2026 | +8.9% | $4.79 | — | — |
| ▼ Q1 FY2026 | Feb 25, 2026 | -577.8% | $4.79 | — | — |
| ▼ Q4 FY2025 | Nov 6, 2025 | -58.5% | $4.19 | $4.01 | -4.30% |
| ▲ Q3 FY2025 | Aug 7, 2025 | +0.0% | $3.79 | $3.70 | -2.37% |
| ▼ Q2 FY2025 | May 9, 2025 | -15.0% | $2.67 | $2.54 | -4.87% |
| ▼ Q1 FY2025 | Feb 27, 2025 | -69.6% | $4.39 | $4.23 | -3.64% |
| ▲ Q4 FY2024 | Nov 7, 2024 | +6.3% | $7.00 | $7.50 | +7.14% |
| ▲ Q3 FY2024 | Aug 1, 2024 | +6.7% | $31.90 | $32.50 | +1.88% |
Q2 FY2026—
Report Date
May 7, 2026
EPS Beat/Miss
+8.9%
Price Before
$4.79
Price After
—
Q1 FY2026—
Report Date
Feb 25, 2026
EPS Beat/Miss
-577.8%
Price Before
$4.79
Price After
—
Q4 FY2025-4.30%
Report Date
Nov 6, 2025
EPS Beat/Miss
-58.5%
Price Before
$4.19
Price After
$4.01
Q3 FY2025-2.37%
Report Date
Aug 7, 2025
EPS Beat/Miss
+0.0%
Price Before
$3.79
Price After
$3.70
Q2 FY2025-4.87%
Report Date
May 9, 2025
EPS Beat/Miss
-15.0%
Price Before
$2.67
Price After
$2.54
Q1 FY2025-3.64%
Report Date
Feb 27, 2025
EPS Beat/Miss
-69.6%
Price Before
$4.39
Price After
$4.23
Q4 FY2024+7.14%
Report Date
Nov 7, 2024
EPS Beat/Miss
+6.3%
Price Before
$7.00
Price After
$7.50
Q3 FY2024+1.88%
Report Date
Aug 1, 2024
EPS Beat/Miss
+6.7%
Price Before
$31.90
Price After
$32.50
Avg Beat Reaction+2.22%
Avg Miss Reaction-4.27%
Beat Rate4 / 8 quarters
Largest Move+7.14% (Q4 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ATHA ends December
Athira Pharma, Inc. (ATHA) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $-1.73 — beating the analyst consensus of $-1.90 by +8.9%. The next ATHA earnings date is expected around September 1, 2026.
Each quarter, investors track ATHA earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ATHA revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ATHA's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ATHA earnings · 5 questionsAthira Pharma, Inc.'s next earnings report is expected around September 1, 2026. ATHA typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ATHA historically reports after market close (AMC).
ATHA earnings datewhen is ATHA earningsATHA next earnings datewhen does ATHA report earningsATHA earnings calendar
▸ Source: FMP · Athira Pharma, Inc. SEC filings · US GAAP · Athira Pharma, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026